Maddison and Kanichi collaborate to develop PoC test for H. pylori
Kanichi Research Services Ltd and Maddison Ltd have entered into a collaborative agreement to develop a low-cost, disposable, point of care test for the detection and diagnosis of Helicobacter Pylori (H. pylori), a bacterial infection in the gut which can lead to stomach ulcers and stomach cancer.
The Problem: The World Health Organization International Agency for Research on Cancer (IARC) classifies H. pylori as a Group 1 carcinogen. Approximately 89% of non-cardia gastric cancer cases, representing 78% of all gastric cancer cases, are now estimated to be attributable to chronic H. pylori infection. Gastric cancer is the second leading cause of cancer-related deaths globally, primarily due to the fact that it is usually diagnosed very late with no effective treatment. The current test solutions are not point of care as they need to be sent to a laboratory for analysis, with the exception of one solution which requires considerable investment in equipment.
Kanichi-Maddison Solution Advantages: This innovative, non-invasive, diagnostic system integrates a novel disposable electrochemical sensor, into a fully disposable exhaled breath condensate collection device for point of care use.
- Point of care solution with results in 12 minutes.
- No requirement for remote lab testing and sample shipment.
- Ease of use, minimal training, – suitable for pharmacy, nurse or remote clinic use.
- High sensitivity and specificity to match current tests.
- Low cost (sell price expected to be <£15).
- Suitable for widespread use in developing countries.
- No need to buy an expensive analyser.
- No follow-up appointment or letter required.
Market Potential: H. Pylori is widely reported to affect around half of the world’s population. In the UK, 4% of the 340 Million annual GP consultations are related to dyspepsia of which a significant proportion involves an H. pylori test. In the USA the reimbursement for the current test is £93 and the global market potential for tests is understood to be over £100 Million pa.